Related Experiment Video

Updated: Feb 14, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

767

Prognosis of patients with apparent treatment-resistant hypertension-a feasibility study

Peter Hayes1, Hannah Kielty2, Monica Casey1

  • 11Discipline of General Practice, School of Medicine, National University of Ireland, Galway, Ireland.

Pilot and Feasibility Studies
|February 10, 2018
PubMed

Insights

This feasibility study shows that a full cohort study on apparent treatment-resistant hypertension (aTRH) is possible in general practice. The methodology is acceptable, and patient participation is high, supporting future research on aTRH prognosis.

Area of Science:

  • Cardiology
  • General Practice Research
  • Hypertension Management

Background:

  • Apparent treatment-resistant hypertension (aTRH) affects a subset of hypertensive patients requiring further investigation.
  • Existing guidelines highlight the need for research into the prognosis of resistant hypertension.
  • This study addresses the feasibility of researching aTRH within a general practice setting.

Purpose of the Study:

  • To assess the feasibility of a full cohort study for patients with apparent treatment-resistant hypertension (aTRH).
  • To determine practice and patient participation rates in a general practice setting.
  • To evaluate the availability of outcome measures and data collection times for aTRH research.

Main Methods:

  • A feasibility study was conducted in three general practices within a university research network.
  • Patient identification and recruitment strategies for a planned full cohort study were tested.
  • Data collection procedures and outcome measures were assessed for efficiency and completeness.

Main Results:

  • All three participating practices demonstrated full engagement.
  • High patient follow-up (98%) was achieved over a median of 23 months.
  • Key outcomes included new-onset retinopathy (9 cases) and a composite outcome of death or cardiovascular events (8%).
  • Average systolic blood pressure improved by 5 mmHg, and eGFR increased.
  • Data collection per patient averaged 12 minutes.

Conclusions:

  • The proposed methodology for a full cohort study of aTRH patients in general practice is feasible and acceptable.
  • The study supports the possibility of conducting an adequately powered follow-up study.
  • This research paves the way for future investigations into the prognosis of apparent treatment-resistant hypertension.
Abstract

Keywords:
FeasibilityHypertensionPrimary carePrognosisTreatment resistant hypertension

More Related Videos

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

683
Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex06:04

Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex

Published on: July 4, 2018

9.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Apparent Weight01:09

Apparent Weight

True weight is the measure of the gravitational force acting on an object. However, if the object accelerates, its measured weight is different from its true weight. Similar observations can be made when the object is submerged in water. An object's weight in water is its apparent weight, which is equal to the difference between its true weight and the buoyant forces.
Consider a person standing on a bathroom scale inside an elevator. If the scale is accurate at rest, its reading equals the...
9.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
630
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
489
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
642